Its also worth considering that we may receive a hybrid response. Ie we may be approved to treat severe patients, and asked to complete a larger, phase 3 trial for mild to moderate.

I would be disappointed with this, but as I've said before, the publicity of being THE treatment for severe patients would greatly accelerate the enrollment into the mild to moderate trials.